Médecine Intensive Réanimation Détresses Respiratoires et Infection Sévères, AP-HM, CHU Nord, Marseille, France.
CEReSS - Center for Studies and Research on Health Services and Quality of Life EA3279, Aix-Marseille University, Marseille, France.
Crit Care Med. 2020 Oct;48(10):e971-e975. doi: 10.1097/CCM.0000000000004504.
The main objective of the study was to determine the prevalence of venous thromboembolism events in patients infected with severe acute respiratory syndrome coronavirus 2 requiring venovenous extracorporeal membrane oxygenation. The secondary objective was to compare venous thromboembolism events and coagulation variables in patients requiring venovenous extracorporeal membrane oxygenation according to the pathogen.
Retrospective observational analysis at a single center.
Tertiary referral university teaching hospital.
Patients with severe acute respiratory syndrome coronavirus 2-related severe acute respiratory distress syndrome requiring venovenous extracorporeal membrane oxygenation therapy with an injected CT scan performed after extracorporeal membrane oxygenation retrieval.
None.
We included 13 severe acute respiratory syndrome coronavirus 2 patients requiring venovenous extracorporeal membrane oxygenation. All of these patients experienced venous thromboembolism: 10 patients (76.9%) had isolated cannula-associated deep vein thrombosis, two patients (15.4%) had isolated pulmonary embolism, and one patient (7.7%) had both cannula-associated deep vein thrombosis and pulmonary embolism. Eleven patients (84.6%) had cannula-associated deep vein thrombosis. A jugular associated cannula-associated deep vein thrombosis was identified in seven patients (53.8%), a femoral associated cannula-associated deep vein thrombosis was identified in 10 patients (76.9%), and six patients (46.2%) had both femoral and jugular cannula-associated deep vein thrombosis. A pulmonary embolism was found in three patients (23.1%). No patient had central venous catheter-related deep vein thrombosis. One patient had thrombotic occlusion of the centrifugal pump, and one had oxygenator thrombosis requiring circuit replacement. Three patients (23.1%) had significant bleeding. Three patients (23.1%) had laboratory-confirmed heparin-induced thrombocytopenia, and all of them developed cannula-associated deep vein thrombosis. These three patients had femoral cannula-associated deep vein thrombosis, and two had an oxygenator or pump thrombosis. The mean activated partial thromboplastin time ratio was higher in the severe acute respiratory syndrome coronavirus 2 group than in the influenza group and the community-acquired pneumonia group (1.91 vs 1.48 vs 1.53; p = 0.001), which was also found in regard to the percentage of patients with an activated partial thromboplastin time ratio greater than 1.8 (47.8% vs 20% vs 20.9%; p = 0.003) and the mean prothrombin ratio (86.3 vs 61.6 vs 67.1; p = 0.003). There was no difference in baseline characteristics or venous thromboembolism events.
We report a 100% occurrence of venous thromboembolism in critically ill patients supported by venovenous extracorporeal membrane oxygenation for severe acute respiratory syndrome coronavirus 2-related acute respiratory distress syndrome using CT scan imaging despite a high target and close monitoring of anticoagulation.
本研究的主要目的是确定需要静脉-静脉体外膜肺氧合(VV-ECMO)治疗的严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2)感染患者中静脉血栓栓塞(VTE)事件的发生率。次要目的是比较因病原体不同而需要 VV-ECMO 的患者的 VTE 事件和凝血变量。
单中心回顾性观察性分析。
三级转诊大学教学医院。
因 SARS-CoV-2 相关严重急性呼吸窘迫综合征需要 VV-ECMO 治疗且在 ECMO 取出后进行注射 CT 扫描的患者。
无。
我们纳入了 13 例需要 VV-ECMO 的 SARS-CoV-2 患者。所有这些患者均发生 VTE:10 例(76.9%)为单纯导管相关深静脉血栓形成,2 例(15.4%)为单纯肺栓塞,1 例(7.7%)为导管相关深静脉血栓形成和肺栓塞。11 例(84.6%)患者发生导管相关深静脉血栓形成。7 例(53.8%)患者出现颈内静脉导管相关深静脉血栓形成,10 例(76.9%)患者出现股静脉导管相关深静脉血栓形成,6 例(46.2%)患者同时出现股静脉和颈内静脉导管相关深静脉血栓形成。3 例(23.1%)患者出现肺栓塞。无患者发生中心静脉导管相关深静脉血栓形成。1 例患者出现离心泵血栓形成,1 例患者出现氧合器血栓形成需要更换回路。3 例(23.1%)患者发生明显出血。3 例(23.1%)患者实验室确诊肝素诱导的血小板减少症(HIT),且均发生导管相关深静脉血栓形成。这 3 例患者均为股静脉导管相关深静脉血栓形成,2 例患者发生氧合器或泵血栓形成。与流感组和社区获得性肺炎组相比,SARS-CoV-2 组的活化部分凝血活酶时间比值(APTT)更高(1.91 比 1.48 比 1.53;p = 0.001),APTT 比值大于 1.8 的患者比例也更高(47.8% 比 20% 比 20.9%;p = 0.003),凝血酶原比值也更高(86.3 比 61.6 比 67.1;p = 0.003)。两组患者的基线特征和 VTE 事件无差异。
尽管抗凝治疗的目标较高且监测密切,但我们通过 CT 扫描影像学发现,在因 SARS-CoV-2 相关急性呼吸窘迫综合征而接受 VV-ECMO 支持的危重症患者中,VTE 发生率为 100%。